Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation
J Antimicrob Chemother
.
2022 Nov 28;77(12):3526-3527.
doi: 10.1093/jac/dkac316.
Authors
Beatrijs Mertens
1
2
,
Ruth Van Daele
1
2
,
Yves Debaveye
3
4
,
Joost Wauters
5
6
,
Christophe Vandenbriele
7
8
,
Roger Brüggemann
9
,
Matthias Gijsen
1
2
,
Isabel Spriet
1
2
Affiliations
1
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
2
Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
3
Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
4
Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
5
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
6
Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
7
Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
8
Department of Adult Intensive Care, Royal Brompton & Harefield NHS Foundation Trust, London, UK.
9
Pharmacy Department, Radboud University Medical Center, Nijmegen, The Netherlands.
PMID:
36124899
DOI:
10.1093/jac/dkac316
No abstract available
Publication types
Editorial
Comment
MeSH terms
Critical Illness
Extracorporeal Membrane Oxygenation*
Humans
Nitriles
Triazoles / therapeutic use
Substances
isavuconazole
Triazoles
Nitriles